At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden, London, UK, discusses the phase 3 CheckMate 067 trial. The results of this trial demonstrate a superior progression-free survival of nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) regimen or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews